List of Peptides and What They Do
Peptides are short chains of amino acids, and the ones people search for fall into six groups: weight-loss (GLP-1) drugs, repair and recovery, skin and hair, growth hormone, brain and mood, and a mixed group of everything else. Only a few are FDA-approved drugs, each for a named use: semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), tesamorelin (Egrifta), bremelanotide (Vyleesi), oxytocin (Pitocin) and elamipretide (Forzinity). The others, including retatrutide, BPC-157, TB-500, ipamorelin and CJC-1295, had no FDA-approved product in Drugs@FDA when we searched on 31 October 2026.
Updated 31 October 2026. FDA labels, Drugs@FDA records and papers were checked on 31 October 2026, and the sources are listed at the end.
The legal picture moved this week. On 30 October 2026 HHS published a Federal Register notice (2026-22192, 91 FR 68526) with an interim enforcement discretion policy for 503A compounding of six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. It says HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility or licensed physician compounding with those substances under the policy, and that the policy is not binding on HHS or the public. It is not an FDA approval, and the notice itself says compounded drugs are not FDA-approved. Our plain-English explainer and the legal status guide cover what it does and does not change.
How to Read the Status Column
- FDA approved means the product has an FDA drug label, and the row names the labelled use. It does not cover every use people try.
- No FDA-approved product means a Drugs@FDA search by the substance name returned no record on 31 October 2026. It says nothing, good or bad, about whether the compound works.
- Paper cited means the row names the paper it relies on. A row that cites none is not claiming that human efficacy data exist.
The Full List
Metabolic and weight
| Peptide | Also called | Type | FDA status and evidence |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy | GLP-1 receptor agonist | FDA approved. Wegovy is labelled to reduce excess body weight and maintain the loss in adults with obesity, or with overweight plus a weight-related condition, among other uses. In the Wegovy label's Study 1, mean weight change was -14.9% versus -2.4% on placebo over 68 weeks. |
| Tirzepatide | Mounjaro, Zepbound | GIP and GLP-1 receptor agonist | FDA approved. Zepbound is labelled for weight reduction and for moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro is labelled for type 2 diabetes. In the Zepbound label's Study 1, mean weight change on 15 mg was -20.9% versus -3.1% on placebo, with treatment for up to 72 weeks. |
| Retatrutide | LY3437943 | GIP, GLP-1 and glucagon receptor agonist | No FDA-approved product found in Drugs@FDA. Phase 2 trial (NEJM, 2023): mean weight change at 48 weeks was -24.2% on 12 mg versus -2.1% on placebo. |
| Mazdutide | IBI362 | GLP-1 and glucagon dual agonist | No FDA-approved product found in Drugs@FDA. |
| Cagrilintide | Amylin analogue | No FDA-approved product found in Drugs@FDA. | |
| AOD-9604 | Growth hormone fragment | No FDA-approved product found in Drugs@FDA. | |
| HGH Fragment 176-191 | Growth hormone fragment | No FDA-approved product found in Drugs@FDA. | |
| 5-Amino-1MQ | NNMT inhibitor | No FDA-approved product found in Drugs@FDA. | |
| MOTS-c | Mitochondrial-derived peptide | No FDA-approved product found in Drugs@FDA. One of the six peptides named in the HHS notice of 30 October 2026. |
Repair, recovery and immune
| Peptide | Also called | Type | FDA status and evidence |
|---|---|---|---|
| BPC-157 | Body Protection Compound | Synthetic pentadecapeptide | No FDA-approved product found in Drugs@FDA. A systematic review published in October 2026 found three small human studies (30 people in total), rated the certainty of evidence very low, and advised against clinical use outside regulated trials. One of the six peptides named in the HHS notice of 30 October 2026. |
| TB-500 | Thymosin beta-4 fragment (LKKTETQ) | Seven amino acid fragment of thymosin beta-4 | No FDA-approved product found in Drugs@FDA. A J Am Acad Orthop Surg review (27 October 2026) says TB-500 is often confused with full-length thymosin beta-4, and that direct musculoskeletal evidence for thymosin beta-4 is limited to in vitro and rodent studies. One of the six peptides named in the HHS notice of 30 October 2026. |
| KPV | Tripeptide | No FDA-approved product found in Drugs@FDA. One of the six peptides named in the HHS notice of 30 October 2026. | |
| Thymosin alpha-1 | Zadaxin | Thymosin peptide | No FDA-approved product found in Drugs@FDA. |
| Wolverine stack | BPC-157 + TB-500 | Blend of two peptides | Neither component has an FDA-approved product. |
Skin and hair
| Peptide | Also called | Type | FDA status and evidence |
|---|---|---|---|
| GHK-Cu | Copper peptide | Copper-binding peptide | No FDA-approved product found in Drugs@FDA. |
| AHK-Cu | Copper peptide | No FDA-approved product found in Drugs@FDA. | |
| Argireline | Acetyl hexapeptide-8 | Topical peptide | No FDA-approved product found in Drugs@FDA. |
| Matrixyl 3000 | Palmitoyl peptides | Topical peptide blend | No FDA-approved product found in Drugs@FDA. |
| SNAP-8 | Acetyl octapeptide-3 | Topical peptide | No FDA-approved product found in Drugs@FDA. |
| GLOW | GHK-Cu + BPC-157 + TB-500 | Blend of three compounds | None of the three components has an FDA-approved product. |
| KLOW | GLOW + KPV | Blend of four compounds | None of the four components has an FDA-approved product. |
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutesGrowth hormone and muscle
| Peptide | Also called | Type | FDA status and evidence |
|---|---|---|---|
| Sermorelin | GHRH 1-29 | GHRH analogue | Brand Geref was FDA approved (two applications from 1990 and 1997). Drugs@FDA lists both as discontinued. |
| Ipamorelin | Growth hormone secretagogue | No FDA-approved product found in Drugs@FDA. FDA lists ipamorelin acetate in Category 2 for 503B outsourcing facilities (page current as of 22 April 2026). | |
| CJC-1295 | Modified GRF 1-29 | GHRH analogue | No FDA-approved product found in Drugs@FDA. |
| Tesamorelin | Egrifta | Growth hormone-releasing factor analogue | FDA approved. Egrifta WR is labelled to reduce excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight loss management. |
| GHRP-2 | Growth hormone releasing peptide | No FDA-approved product found in Drugs@FDA. FDA lists GHRP-2 in Category 2 for 503B (injectable and nasal routes), page current as of 22 April 2026. | |
| GHRP-6 | Growth hormone releasing peptide | No FDA-approved product found in Drugs@FDA. FDA lists GHRP-6 in Category 2 for 503B (page current as of 22 April 2026). | |
| Hexarelin | Growth hormone secretagogue | No FDA-approved product found in Drugs@FDA. | |
| MK-677 | Ibutamoren | Growth hormone secretagogue | No FDA-approved product found in Drugs@FDA. FDA lists ibutamoren in Category 2 (page current as of 22 April 2026). |
| IGF-1 LR3 | Long-acting IGF-1 analogue | No FDA-approved product found in Drugs@FDA. | |
| Follistatin 344 | Follistatin isoform | No FDA-approved product found in Drugs@FDA. |
Brain, mood and sleep
| Peptide | Also called | Type | FDA status and evidence |
|---|---|---|---|
| Selank | Tuftsin analogue | No FDA-approved product found in Drugs@FDA. | |
| Semax | ACTH fragment analogue | No FDA-approved product found in Drugs@FDA. One of the six peptides named in the HHS notice of 30 October 2026. | |
| Dihexa | Research compound | No FDA-approved product found in Drugs@FDA. | |
| DSIP | Delta sleep-inducing peptide | Neuropeptide | No FDA-approved product found in Drugs@FDA. |
Everything else
| Peptide | Also called | Type | FDA status and evidence |
|---|---|---|---|
| PT-141 | Bremelanotide, Vyleesi | Melanocortin receptor agonist | FDA approved. Vyleesi is labelled for premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is not indicated for postmenopausal women or men. |
| Kisspeptin | Reproductive hormone peptide | No FDA-approved product found in Drugs@FDA. FDA lists kisspeptin-10 in Category 2 for 503A (page current as of 22 April 2026). | |
| Oxytocin | Hormone | FDA approved. Pitocin is labelled for obstetric use, including induction of labor for a medical indication, and is given intravenously or intramuscularly. | |
| Melanotan II | MT-2 | Melanocortin agonist | No FDA-approved product found in Drugs@FDA. |
| Epithalon | Epitalon | Tetrapeptide | No FDA-approved product found in Drugs@FDA. One of the six peptides named in the HHS notice of 30 October 2026. |
| NAD+ | Not a peptide. Metabolic cofactor | Not a peptide. Included because it is often miscategorised as one. | |
| SS-31 | Elamipretide | Mitochondria-targeted peptide | FDA approved under accelerated approval as Forzinity, to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. Continued approval may depend on a confirmatory trial. |
What Peptides Are
A peptide is a chain of amino acids. The Egrifta WR label, for example, describes tesamorelin as a synthetic analog of growth hormone-releasing factor with a 44 amino acid sequence. The Bureau uses the word the way the market does, so a few non-peptides, NAD+ among them, appear in the tables and are marked as such. See what counts as a peptide and peptide supplements.
The Honest Summary of This List
Counted by FDA status, the list is lopsided. Six compounds on it have an FDA-approved product with a labelled use: semaglutide, tirzepatide, tesamorelin, bremelanotide, oxytocin and elamipretide. Sermorelin had one, now discontinued. Every other compound has no FDA-approved product in Drugs@FDA. Where human data exist for those, the papers we opened are small: the BPC-157 systematic review counted three studies and 30 people. Retatrutide is the clearest exception for trial size, with a 338-person phase 2 trial in the New England Journal of Medicine, but it has no FDA approval.
None of that makes the unapproved compounds uninteresting to research. It makes them a different proposition from an approved drug, and the status column is there so you can see which is which before paying for either.
Where to Go From Here
- By goal: weight loss, muscle growth, recovery, longevity.
- Practical: reconstitution, injection technique, storage, and the dosing calculator.
- Buying: the vendor scorecard, daily price tracker, how to read a certificate of analysis.
- Context: legal status, what counts as a peptide, cycle lengths.
See also: what a peptide is and where peptides end and proteins begin.
Frequently Asked Questions
What is the list of peptides and what do they do?
The peptides on this list fall into six groups: weight loss, repair and recovery, skin and hair, growth hormone, brain and mood, and everything else. The ones with an FDA-approved use are semaglutide and tirzepatide (weight reduction, and type 2 diabetes for Mounjaro), tesamorelin (excess abdominal fat in HIV-infected adults with lipodystrophy), bremelanotide (hypoactive sexual desire disorder in premenopausal women), oxytocin (obstetric use) and elamipretide (Barth syndrome). For the rest, this page gives what each compound is and its FDA status, and does not claim a benefit.
What do peptides do for the body?
It depends on the peptide. Approved peptide drugs do specific, labelled things: Wegovy and Zepbound are labelled to reduce excess body weight and maintain the loss, Egrifta WR is labelled to reduce excess abdominal fat in HIV-infected adults with lipodystrophy, Vyleesi is labelled for low sexual desire disorder in premenopausal women, and Pitocin is labelled for obstetric use. Compounds with no FDA-approved product have no FDA-reviewed use.
Which peptides are FDA-approved?
Among the compounds on this list: semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), tesamorelin (Egrifta), bremelanotide (Vyleesi), oxytocin (Pitocin and generic products) and elamipretide (Forzinity, under accelerated approval). Sermorelin's brand Geref was approved but is listed as discontinued. We checked current labels on DailyMed and records in Drugs@FDA on 31 October 2026.
Which peptides on the list have no FDA-approved product?
A Drugs@FDA search by name on 31 October 2026 found no record for retatrutide, mazdutide, cagrilintide, BPC-157, TB-500, KPV, thymosin alpha-1, AOD-9604, ipamorelin, CJC-1295, GHK-Cu, semax, selank, melanotan II, epitalon, MOTS-c, dihexa and others on the list. No approval means FDA has not approved the product for any use. It does not say whether the compound works.
Is there human evidence for BPC-157?
Very little. A systematic review published in October 2026 in Acta Orthopaedica Belgica found three human studies with 30 people in total: a retrospective study of knee injections, a retrospective pilot study for interstitial cystitis and a pilot study of intravenous safety. The authors judged the studies to be of poor methodological quality, rated the certainty of the evidence very low, and concluded that BPC-157 should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials.
What did HHS say about compounding peptides on 30 October 2026?
HHS published an interim enforcement discretion policy in the Federal Register (notice 2026-22192) for 503A compounding of six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. It says HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility or licensed physician compounding with those substances under the policy, and that the policy is not binding. It is not an FDA approval: the notice itself says compounded drugs are not FDA-approved.
How are peptide drugs taken?
The approved products above are mostly injected. The Zepbound, Mounjaro, Egrifta WR and Vyleesi labels describe subcutaneous injection, and Pitocin is labelled for intravenous and intramuscular use. Semaglutide also comes as a tablet, as Rybelsus and as a Wegovy tablet in the current Wegovy label.
Sources
Every source below was opened on 31 October 2026.
- Wegovy prescribing information (label version published 30 June 2026). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b. Checked 31 October 2026.
- Zepbound prescribing information (published 2 September 2026). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b. Checked 31 October 2026.
- Mounjaro prescribing information (published 2 September 2026). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0. Checked 31 October 2026.
- Egrifta WR prescribing information (published 3 August 2026). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75. Checked 31 October 2026.
- Vyleesi prescribing information (published 18 November 2025). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf. Checked 31 October 2026.
- Pitocin prescribing information (published 21 May 2026). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e5a66fc-e507-497c-b5ce-44a8c95898ad. Checked 31 October 2026.
- Forzinity prescribing information (published 12 December 2025). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75. Checked 31 October 2026.
- Drugs@FDA application records, searched by active ingredient through the openFDA drugsfda endpoint. https://open.fda.gov/apis/drug/drugsfda/. Checked 31 October 2026.
- Jastreboff et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a Phase 2 Trial, N Engl J Med 2023;389:514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/. Checked 31 October 2026.
- Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety, Acta Orthopaedica Belgica, October 2026. https://pubmed.ncbi.nlm.nih.gov/42885452/. Checked 31 October 2026.
- Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500, J Am Acad Orthop Surg, 27 October 2026. https://pubmed.ncbi.nlm.nih.gov/42937313/. Checked 31 October 2026.
- FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks. Checked 31 October 2026.
- HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Federal Register notice 2026-22192, 91 FR 68526, 30 October 2026. https://www.federalregister.gov/d/2026-22192. Checked 31 October 2026.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutes